ID   WeWak1
AC   CVCL_E871
SY   Wewak1; WEWAK1; Wewak-1
DR   Cosmic; 2804851
DR   dbMHC; 49061
DR   ECACC; 94022553
DR   IHW; IHW09219
DR   IPD-IMGT/HLA; 11558
DR   Wikidata; Q54993790
RX   PubMed=8108117;
RX   PubMed=9583678;
RX   PubMed=25787276;
RX   PubMed=30844424;
CC   Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC   Population: Papuan.
CC   Virology: Contains a complete EBV genome (strain WeWak1) which has been sequenced (PubMed=25787276).
CC   HLA typing: A*11:01,24:02; B*27:04:01,15:06; C*04:01,12:02; DPB1*01:01:01,03:01 (IPD-IMGT/HLA=11558).
CC   Sequence variation: Mutation; HGNC; HGNC:7553; MYC; Simple; p.Pro72Thr (c.214C>A); Zygosity=Unspecified (PubMed=8108117).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Caution: Could be identical to QIMR-WW1-LCL (Cellosaurus=CVCL_W930).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Transformed cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 19
//
RX   PubMed=8108117;
RA   Albert T., Urlbauer B., Kohlhuber F., Hammersen B., Eick D.;
RT   "Ongoing mutations in the N-terminal domain of c-Myc affect
RT   transactivation in Burkitt's lymphoma cell lines.";
RL   Oncogene 9:759-763(1994).
//
RX   PubMed=9583678; DOI=10.1038/sj.onc.1201704;
RA   Brimmell M., Mendiola R., Mangion J., Packham G.;
RT   "BAX frameshift mutations in cell lines derived from human
RT   haemopoietic malignancies are associated with resistance to apoptosis
RT   and microsatellite instability.";
RL   Oncogene 16:1803-1812(1998).
//
RX   PubMed=25787276; DOI=10.1128/JVI.03614-14; PMCID=PMC4442510;
RA   Palser A.L., Grayson N.E., White R.E., Corton C., Correia S.,
RA   Ba Abdullah M.M., Watson S.J., Cotten M., Arrand J.R., Murray P.G.,
RA   Allday M.J., Rickinson A.B., Young L.S., Farrell P.J., Kellam P.;
RT   "Genome diversity of Epstein-Barr virus from multiple tumor types and
RT   normal infection.";
RL   J. Virol. 89:5222-5237(2015).
//
RX   PubMed=30844424; DOI=10.1016/j.humimm.2019.03.001; PMCID=PMC6599558;
RA   Creary L.E., Guerra S.G., Chong W., Brown C.J., Turner T.R.,
RA   Robinson J., Bultitude W.P., Mayor N.P., Marsh S.G.E., Saito K.,
RA   Lam K., Duke J.L., Mosbruger T.L., Ferriola D., Monos D.S., Willis A.,
RA   Askar M., Fischer G.F., Saw C.L., Ragoussis J., Petrek M.,
RA   Serra-Pages C., Juan Otero M., Stavropoulos-Giokas C., Dinou A., Ameen R.,
RA   Al Shemmari S., Spierings E., Gendzekhadze K., Morris G.P., Zhang Q.-H.,
RA   Kashi Z., Hsu S., Gangavarapu S., Mallempati K.C., Yamamoto F.,
RA   Osoegawa K., Vayntrub T., Chang C.-J., Hansen J.A.,
RA   Fernandez-Vina M.A.;
RT   "Next-generation HLA typing of 382 International Histocompatibility
RT   Working Group reference B-lymphoblastoid cell lines: report from the
RT   17th International HLA and Immunogenetics Workshop.";
RL   Hum. Immunol. 80:449-460(2019).
//